Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Virology. 2015 Oct 27;487:112–120. doi: 10.1016/j.virol.2015.10.003

Figure 6. Differential effects of LPV products on the tumor suppressor p53.

Figure 6

A) Evaluation of p53 protein levels in various cell types as determined by western blot. B). Real time PCR analysis of p53 target genes in MEFs expressing different LPV products. The target genes were normalized against the Rpl5 gene and the expression levels in wt MEFs were used as baseline control. C) Differential interactions between LPV products and p53 as revealed by Immunoprecipitation with Xt7 (anti J-domain antibody recognizing the different LPV products) and subsequent western blot analysis with anti-p53. Immunoprecipitations were carried out in the absence (−Ab) or presence (+Ab) of anti-LPV J-domain antibody. Input (I), supernantant (S), immunoprecipitated complex (IP). D) LPV sT prevents p53 up-regulation induced by a DNA damaging agent. Cells were treated with or without doxorubicin and the levels of p53 evaluated by Western Blot. GAPDH was used as loading control.